EMA Rejected Single-Trial Drug Approval Standard
The European regulator argued that multi-trial requirements ensure necessary evidence robustness across clinical settings.
Updated on Sept. 29, 2026 in Biotech
Live Poll
Should government agencies prioritize faster drug approvals over requiring multiple clinical trials for new medicines?
The European Medicines Agency has published an editorial opposing the shift toward single-study drug approvals. The agency asserts that requiring multiple trials is essential to ensure findings remain robust across different clinical settings.
Why it matters
The position marks a formal divergence from the U.S. Food and Drug Administration, which adopted a one-pivotal-study policy in June 2026. This disagreement highlights a fundamental rift in global regulatory strategy regarding the appropriate threshold for clinical safety and efficacy.
The EMA argues that multiple trials provide critical robustness across clinical settings, contrasting with the single pivotal study policy adopted by the FDA in June 2026.
The players
European Medicines Agency
The regulatory body responsible for the scientific evaluation, supervision, and safety monitoring of medicines in the European Union.
Food and Drug Administration
The U.S. federal agency overseeing food safety, dietary supplements, and pharmaceutical drugs through clinical review processes.
Vinay Prasad
A researcher and former FDA figure who advocated for the move toward single-trial approval standards.
Marty Makary
A medical researcher and former FDA figure who co-announced the shift away from the two-trial requirement.
The details
Regulators propose that developers must instead conduct a formal assessment of existing evidence to identify specific knowledge gaps. Developers are advised to structure their evidence generation plans to answer these targeted research questions, ensuring that the clinical benefits of a new treatment clearly outweigh its potential risks. This approach prioritizes a comprehensive understanding of drug behavior over fixed, arbitrary requirements for the total number of clinical trials.
Timeline
February 2026: FDA executives announced the end of the two-trial dogma.
June 2026: The FDA adopted the one pivotal study policy.
September 2026: EMA leadership outlined the agency's views on clinical evidence generation.
The Tech Race
The EMA's stance marks a significant divergence from the policy trajectory set by the FDA's one pivotal study policy. This creates a fragmented regulatory landscape that developers must navigate when seeking international drug approval.
Pharmaceutical developers and clinical researchers will face increasingly complex compliance requirements when pursuing simultaneous approvals in both the U.S. and European markets. This regulatory split may lead to longer development timelines for drugs targeting international patient populations.
The takeaway
The EMA's firm commitment to multi-trial evidence signals a push for conservative safety standards despite recent liberalization in the U.S. Researchers should watch for forthcoming guidance documents that clarify how these differing requirements will impact global trial designs.
Further reading
For more on the changing landscape of clinical evidence, see our latest coverage in Biotech.
Source note: This article includes information reported by BioXconomy.
Live Poll
Should government agencies prioritize faster drug approvals over requiring multiple clinical trials for new medicines?
